LENZ THERAPEUTICS, INC. Payments to Acquire Debt Securities, Available-for-sale
LENZ THERAPEUTICS, INC. (LENZ) reported Payments to Acquire Debt Securities, Available-for-sale of $23.43 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-11
- LENZ THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $7.37M, a 87.35% decline year-over-year.
- LENZ THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $16.06M, a 51.48% decline year-over-year.
- LENZ THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $133.11M, a 185.56% increase year-over-year.
- LENZ THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $56.31M, a 33.00% decline year-over-year.
- LENZ THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2025 was $280.80M, a 16.08% increase from fiscal 2024.
- LENZ THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2024 was $241.91M, a 364.40% increase from fiscal 2023.
- LENZ THERAPEUTICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $52.09M.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $23.43M 10-Q · filed 2026-08-11 | $156.54M derived: sum of 3 quarters · filed 2026-08-11 | $212.85M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $16.06M 10-Q · filed 2026-05-11 | $149.17M derived: sum of 2 quarters · filed 2026-05-11 | $205.47M derived: sum of 3 quarters · filed 2026-05-11 | $263.77M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $133.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $189.42M derived: sum of 2 quarters · filed 2026-03-24 | $247.71M derived: sum of 3 quarters · filed 2026-08-11 | $280.80M 10-K · filed 2026-03-24 |
| 2025-09-30 | $56.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $114.60M derived: sum of 2 quarters · filed 2026-08-11 | $147.69M 10-Q · filed 2025-11-05 | $194.31M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $58.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $91.39M 10-Q · filed 2026-08-11 | $138.00M derived: sum of 3 quarters · filed 2026-08-11 | $222.04M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $33.09M 10-Q · filed 2026-05-11 | $79.70M derived: sum of 2 quarters · filed 2026-05-11 | $163.75M derived: sum of 3 quarters · filed 2026-05-11 | $275.00M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $46.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $130.65M derived: sum of 2 quarters · filed 2026-03-24 | $241.91M derived: sum of 3 quarters · filed 2026-03-24 | $241.91M 10-K · filed 2026-03-24 |
| 2024-09-30 | $84.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $195.30M derived: sum of 2 quarters · filed 2025-11-05 | $195.30M 10-Q · filed 2025-11-05 | $201.12M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $111.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | $111.26M 10-Q · filed 2025-07-30 | $117.08M derived: sum of 3 quarters · filed 2025-07-30 | $136.50M derived: sum of 4 quarters · filed 2025-07-30 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-07 | $5.83M derived: sum of 2 quarters · filed 2025-05-07 | $25.24M derived: sum of 3 quarters · filed 2025-05-07 | |
| 2023-12-31 | $5.83M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $25.24M derived: sum of 2 quarters · filed 2025-03-19 | $52.09M 10-K · filed 2025-03-19 | |
| 2023-09-30 | $19.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $46.26M 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | $26.85M 10-Q · filed 2024-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |